Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
XRAY heads into its November 5 earnings with a painful gap between what insiders were willing to pay and where the market has since taken it.
In June, six directors bought shares in the open market at prices ranging from roughly $9.88 to $10.15. The purchases were small in dollar terms, totalling around $616,000 across the cluster, but the breadth was notable: six separate board members stepping in at similar prices within a four-day window. None were made under a 10b5-1 trading plan. The stock closed Tuesday at $8.52, about 15% below what those directors paid. The gap is a reminder that insider buying is a sentiment signal, not a floor.
Short interest sits at just under 12% of the free float, which is a meaningful level for a healthcare-supplies name. That figure has risen roughly 19% over the past month as the stock dropped 25%. The lending market, however, carries no distress signal. Availability is extremely loose at 435%, meaning there are more than four shares available to borrow for every one already on loan, well above the 52-week tightest point of 336%. Cost to borrow is low at 0.38%, down around 20% on the week. Short sellers are not being squeezed out of their positions, and new shorts face little friction entering. The ORTEX short score has held in a narrow band around 59 to 61 over recent weeks, reflecting no sharp directional shift despite the price slide.
Options positioning is mildly defensive but not alarmed. The put/call ratio is 0.41, a touch above its 20-day average of 0.40 but well within a normal range for this name and far below the 52-week high of 1.21. At a z-score of 0.73, there is no meaningful hedge rush visible in the options market. Calls still dominate the activity, which looks slightly inconsistent with a stock that has lost a quarter of its value in a month.
The Street's posture reflects deep uncertainty rather than conviction either way. The consensus mean price target is $13.40 against the current price of $8.52, implying roughly 57% upside on paper. The important caveat is how those targets have moved. BMO Capital, which initiated coverage in July with a Market Perform at $12, had already cut its target to $10 by mid-September as the stock continued to deteriorate. Barclays holds an Underweight and lifted its target to $11 in August after cutting to $9 in June, a modest mechanical adjustment rather than a change of view. UBS is the only firm currently carrying a Buy rating, with a $17 target trimmed from $18 in May. Citigroup initiated with a Sell and a $10 target in April. The cluster of targets in the $10 to $11 range from more cautious analysts now sits above the current price, which says less about optimism and more about how quickly the stock has fallen through levels that were already considered bearish. The EV/EBITDA multiple is 6.2x and the PE ratio is 5.7x, both of which have compressed by roughly 25% over the past 30 days.
The bull case rests on restructuring progress and the elimination of the dividend, which management framed as a decision to prioritise debt reduction over income payments. The bear case is more textured: continued executive turnover, a CFO departure in the mix, reduced FY26 profitability guidance, and a dental market that has not yet shown the stabilisation the restructuring plan requires. The analyst consensus-recommendation divergence factor scores in the 94th percentile, which in this context means the Street is unusually split rather than aligned.
Retail attention has picked up. Wikipedia pageview data from the Wikimedia Foundation registered a z-score of 2.04 against XRAY's own 90-day history as of late September, suggesting above-normal interest from retail participants. That is a colour point rather than a revenue signal, but attention this elevated during a sharp price decline often reflects speculative interest in the recovery story.
The last earnings print on August 6 sent the stock down 12% on the day and nearly 16% over the following week. The print before that, in May, produced a 6.7% gain on the day but a 13% loss over the subsequent five sessions. The pattern of initial moves getting reversed, or amplified, in the days after results is the dominant feature of XRAY's recent earnings history. With the next print 29 days away, how management addresses the gap between the restructuring narrative and the continued deterioration in operating guidance will be the central question for investors on both sides.
See the live data behind this article on ORTEX.
Open XRAY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
